Literature DB >> 21963186

Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial.

Wolfgang Göpel1, Angela Kribs, Andreas Ziegler, Reinhard Laux, Thomas Hoehn, Christian Wieg, Jens Siegel, Stefan Avenarius, Axel von der Wense, Matthias Vochem, Peter Groneck, Ursula Weller, Jens Möller, Christoph Härtel, Sebastian Haller, Bernhard Roth, Egbert Herting.   

Abstract

BACKGROUND: Surfactant is usually given to mechanically ventilated preterm infants via an endotracheal tube to treat respiratory distress syndrome. We tested a new method of surfactant application to spontaneously breathing preterm infants to avoid mechanical ventilation.
METHOD: In a parallel-group, randomised controlled trial, 220 preterm infants with a gestational age between 26 and 28 weeks and a birthweight less than 1·5 kg were enrolled in 12 German neonatal intensive care units. Infants were independently randomised in a 1:1 ratio with variable block sizes, to standard treatment or intervention, and randomisation was stratified according to centre and multiple birth status. Masking was not possible. Infants were stabilised with continuous positive airway pressure and received rescue intubation if necessary. In the intervention group, infants received surfactant treatment during spontaneous breathing via a thin catheter inserted into the trachea by laryngoscopy if they needed a fraction of inspired oxygen more than 0·30. The primary endpoint was need for any mechanical ventilation, or being not ventilated but having a partial pressure of carbon dioxide more than 65 mm Hg (8·6 kPa) or a fraction of inspired oxygen more than 0·60, or both, for more than 2 h between 25 h and 72 h of age. Analysis was by intention to treat. This study is registered, number ISRCTN05025922.
FINDINGS: 108 infants were assigned to the intervention group and 112 infants to the standard treatment group. All infants were analysed. On day 2 or 3 after birth, 30 (28%) infants in the intervention group were mechanically ventilated versus 51 (46%) in the standard treatment group (number needed to treat 6, 95% CI 3-20, absolute risk reduction 0·18, 95% CI 0·30-0·05, p=0·008). 36 (33%) infants in the intervention group were mechanically ventilated during their stay in the hospital compared with 82 (73%) in the standard treatment group (number needed to treat: 3, 95% CI 2-4, p<0·0001). The intervention group had significantly fewer median days on mechanical ventilation, (0 days. IQR 0-3 vs 2 days, 0-5) and a lower need for oxygen therapy at 28 days (30 infants [30%] vs 49 infants [45%], p=0·032) compared with the standard treatment group. We recorded no differences between groups for mortality (seven deaths in the intervention group vs five in the standard treatment group) and serious adverse events (21 vs 28).
INTERPRETATION: The application of surfactant via a thin catheter to spontaneously breathing preterm infants receiving continuous positive airway pressure reduces the need for mechanical ventilation. FUNDING: German Ministry of Research and Technology, University of Lübeck, and Chiesi Pharmaceuticals. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963186     DOI: 10.1016/S0140-6736(11)60986-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  101 in total

1.  Nebulization of Poractant alfa via a vibrating membrane nebulizer in spontaneously breathing preterm lambs with binasal continuous positive pressure ventilation.

Authors:  Matthias C Hütten; Elke Kuypers; Daan R Ophelders; Maria Nikiforou; Reint K Jellema; Hendrik J Niemarkt; Carola Fuchs; Markus Tservistas; Roberta Razetti; Federico Bianco; Boris W Kramer
Journal:  Pediatr Res       Date:  2015-08-31       Impact factor: 3.756

2.  Effect of Surfactant Therapy Using Orogastric Tube for Tracheal Catheterization in Preterm Newborns with Respiratory Distress.

Authors:  Rampal Singh Tomar; Ranjit Ghuliani; Dinesh Yadav
Journal:  Indian J Pediatr       Date:  2017-01-03       Impact factor: 1.967

3.  Effects of different surfactant administrations on cerebral autoregulation in preterm infants with respiratory distress syndrome.

Authors:  Xu-Fang Li; Ting-Ting Cheng; Rui-Lian Guan; Hong Liang; Wei-Neng Lu; Jing-Hua Zhang; Mei-Yi Liu; Xin Yu; Jun Liang; Li Sun; Lian Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

Review 4.  Surfactant for Respiratory Distress Syndrome: New Ideas on a Familiar Drug with Innovative Applications.

Authors:  H J Niemarkt; M C Hütten; Boris W Kramer
Journal:  Neonatology       Date:  2017-05-25       Impact factor: 4.035

5.  [Clinicopathological analysis of pulmonary vascular disease in 38 neonates died of respiratory failure].

Authors:  Ning Li; Hong-Wu Chen; Xin-Hua Zhou; Li Liang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

Review 6.  Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.

Authors:  Felicia L Bahadue; Roger Soll
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

Review 7.  The role of surfactant and non-invasive mechanical ventilation in early management of respiratory distress syndrome in premature infants.

Authors:  Narayan Prabhu Iyer; Maroun Jean Mhanna
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

8.  Nasal high-frequency oscillation ventilation in neonates: a survey in five European countries.

Authors:  Hendrik Stefan Fischer; Kajsa Bohlin; Christoph Bührer; Gerd Schmalisch; Malte Cremer; Irwin Reiss; Christoph Czernik
Journal:  Eur J Pediatr       Date:  2014-09-18       Impact factor: 3.183

Review 9.  Surfactant therapy: the current practice and the future trends.

Authors:  Khalid Altirkawi
Journal:  Sudan J Paediatr       Date:  2013

10.  European perspective on less invasive surfactant administration-a survey.

Authors:  Daniel Klotz; Ugo Porcaro; Thilo Fleck; Hans Fuchs
Journal:  Eur J Pediatr       Date:  2016-12-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.